Canakinumab dosing intervals in pediatric colchicine-resistant familial Mediterranean fever (FMF): outcomes and predictors of successful extension in a real-world cohort
Authors' conclusion
Although canakinumab achieves sustained inflammatory suppression, biochemical improvement does not ensure comparable clinical control.
Study context
- Population
- Pediatric patients with colchicine-resistant FMF treated with canakinumab
- Participants
- 60 patients
- Exposure
- Canakinumab dosing interval groups: stable interval vs successful vs unsuccessful interval extension
- Group 1n = 14reference
- Group 2n = 24
- Group 3n = 22
- Outcome
- Clinical and inflammatory outcomes across dosing interval groups; predictors of successful interval extension
Methodological detailssingle-centre, linear mixed-effects models, multivariable logistic regression, Firth's penalized method as sensitivity analysis
- Single-centre
- Linear mixed-effects models
- Multivariable logistic regression
- Firth's penalized method as sensitivity analysis
Main finding
As reported in the abstract
Complete remission rate
P = 0.005
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value | |
|---|---|---|---|
| Arthritis at disease onset as predictor of successful interval extension (multivariable logistic regression)Arthritis at onsetvs No arthritis at onsetIndependently associated · Firth's penalized method as sensitivity analysis | OR for successful interval extension 7.14 (95% CI 1.26–40.41) | P = 0.026 | |
| Arthritis at disease onset as predictor of successful interval extension (multivariable logistic regression)Arthritis at onsetvs No arthritis at onsetConsistent direction · Firth's penalized method as sensitivity analysis | OR for successful interval extension (Firth sensitivity analysis) 5.51 (95% CI 1.08–28.23) | P = 0.081 | |
| 0.050.21520Ratio (log scale) |
Annual attack rate after canakinumab initiation, median (all patients)
- Median annual attack rate before canakinumab, attacks per patient-year
- 7 (4-12)
- Median annual attack rate after canakinumab, attacks per patient-year
- 1.1 (0.5-2.1)
C-reactive protein (CRP) trajectories
- CRP declined rapidly and stabilized after month 3; inflammatory trajectories did not differ across groups
Original publication
Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort. Rheumatology (Oxford). Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →